Report Overview

The UK Migraine Drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Regionally, the UKs migraine drug market is expected to lead the European market due to the growing patient population, changes in lifestyle, ring endorsement of new drug classes, and the invention of peptide-based therapies for the medication of migraine. Around 900,000 adults in the UK are suffering from chronic migraines. The market key players operating in the market are coming with the product and new drug launches and strategic collaborations to toughens their market status. Approval of the new drugs manufactured to treat migrane, headaches, the presence of key players like Pfizer, Eli Lilly, and many more are driving the market. Moreover, the FDA approvals of novel drugs by the key players in the market accelerate the region's growth.



Market Drivers

Rise in prevalence of migraine drives the market. Rise in focus of vendors on the emerging markets is expected to boost the market growth. UK is projected to witness significant growth in future, owing to rise in demand for better healthcare facilities and improvements in healthcare infrastructure. Furthermore, this region presents remarkable opportunities for the venture capitalists and investors, as the developed markets are comparatively saturated. Moreover, increase in female population and surge in awareness among patients related to prevention and treatment of migraine are the key factors that augment the growth of the market. Other important factors impacting the market are focus on organic growth, changes in disposable income, and rapid urbanisation.

However, lack of proper diagnosis and undiagnosed cases, adverse effects of drugs, increased preference for alternative therapies, and generic penetration are the few factors hampering the migraine therapeutics market.